| Identification | Back Directory | [Name]
INCB16562 | [CAS]
933768-63-9 | [Synonyms]
INCB16562
Imidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine, 2-(2,6-dichlorophenyl)-1,8-dihydro- | [Molecular Formula]
C19H11Cl2N5 | [MOL File]
933768-63-9.mol | [Molecular Weight]
380.23 |
| Hazard Information | Back Directory | [Uses]
INCB16562 is an orally active and selective inhibitor against JAK1/2 markedly selective over JAK3. INCB16562 potently inhibits interleukin-6 (IL-6)-induced phosphorylation of STAT3. Additionally, INCB16562 inhibits the proliferation and survival of myeloma cells dependent on IL-6 for growth, as well as the IL-6–induced growth of primary bone marrow-derived plasma cells. INCB16562 antagonizes the growth of myeloma xenografts in mice with antitumor activity. INCB16562 is promising for research of multiple myeloma[1]. | [References]
[1] Li J, et al. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia. 2010 Jan;12(1):28-38. DOI:10.1593/neo.91192 |
|
|